Latest News

The phase 3 NRG-GU005 trial found SBRT improved bowel quality of life vs MH-IMRT but did not improve urinary outcomes or disease-free survival.

Daniel S. Kellner, MD, discusses patient selection for HoLEP and strategies for surgeons interested in adoption.

The NDA submission is supported by data from the phase 3 UTOPIA trial.

Ryan K. Flannigan, MD, discusses phase 2 data showing promising efficacy with sustained-release lidocaine in men with chronic scrotal pain.

A recent study found active surveillance use for low-risk prostate cancer rose from 27% to 93% among veterans from 2005 to 2024.

A national analysis found that 51% of focal therapy procedures for prostate cancer occurred in patients with low-, high-, or very-high-risk disease, outside current guideline-supported settings.

The DIRECT-AI registry has enrolled its first patient to prospectively assess how the ArteraAI Prostate Test influences treatment decisions and outcomes in routine care.

Belzutifan plus lenvatinib significantly improved progression-free survival vs cabozantinib in patients with previously treated advanced clear cell renal cell carcinoma.

Nima Almassi, MD, reviews long-term evidence for bladder preservation after systemic therapy in muscle-invasive bladder cancer.

An analysis of NHANES data found that higher intake of ultra-processed foods was associated with increased prostate cancer risk among US men.

In this episode of Pearls & Perspectives, Amy Pearlman, MD, and plastic surgeon Andrew T. Cohen, MD, FACS, discuss managing patient expectations and the importance of cultivating balance outside of surgical practice.

Narmina Khanmammadova, MD, discusses interim findings on preoperative pelvic floor therapy and its potential to improve continence recovery after HoLEP.

Jessica Yih, MD, reviews evidence on testosterone therapy for female sexual dysfunction, highlighting promising but limited data in premenopausal women.